Clincosm LogoSign in Get a demo

LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting

Sponsor
Karolinska Institutet (Other)
Overall Status
Completed
CT.gov ID
NCT01937676
Collaborator
(none)
1,250
Enrollment
1
Location

Study Details

Study Description

Brief Summary

The purpose of this study is evaluate if K3, a novel biomarker, sampled at arrival to the emergency department can be used to predict the development of organ failure measured as SOFA score. K3 consists of lactate dehydrogenase, albumin and magnesium combined.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1250 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting
    Study Start Date :
    Sep 1, 2013
    Actual Primary Completion Date :
    Apr 1, 2014

    Arms and Interventions

    Arm Intervention/Treatment
    Adults admitted to ER

    All adult patients admitted to emergency department during the study period.

    Outcome Measures

    Primary Outcome Measures

    1. Development of multiple organ failure [30 days or complete ICU stay]

      Measured as SOFA score.

    Secondary Outcome Measures

    1. Cardiac function [30 days or complete ICU stay]

      Is it possible to predict cardiac function with the novel biomarker K3, which consists of lactate dehydrogenase, albumin, and magnesium combined?

    2. All cause mortality [30 days after admission to emergency department]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Age ≥18 years

    • Admitted to emergency department, Karlstad Central Hospital, Sweden

    Exclusion Criteria:
    • Not in need of venous blood sample

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Karlstad Central Hospital Karlstad Sweden

    Sponsors and Collaborators

    • Karolinska Institutet

    Investigators

    • Principal Investigator: Mathias Karlsson, MD, PhD, Karolinska
    • Study Director: Jan Wernerman, MD, Prof, Karolinska
    • Study Director: Lars Wiklund, MD, Prof, Uppsala University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fredrik Helliksson, MD, Karolinska Institutet
    ClinicalTrials.gov Identifier:
    NCT01937676
    Other Study ID Numbers:
    • K3-akuten
    First Posted:
    Sep 9, 2013
    Last Update Posted:
    Sep 7, 2016
    Last Verified:
    Sep 1, 2016
    Additional relevant MeSH terms:
    Emergencies
    Multiple Organ Failure

    Study Results

    No Results Posted as of Sep 7, 2016